Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Oct;70(4):366–370. doi: 10.1136/hrt.70.4.366

Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension.

T W Higenbottam 1, D Spiegelhalter 1, J P Scott 1, V Fuster 1, A T Dinh-Xuan 1, N Caine 1, J Wallwork 1
PMCID: PMC1025334  PMID: 8217447

Abstract

OBJECTIVE--To determine whether epoprostenol (prostacyclin, PGI2) or heart-lung transplantation (HLT), or both improves survival of patients with severe pulmonary hypertension. DESIGN--This was a prospective study where the effects of epoprostenol were compared with conventional treatment. Also, the benefits of epoprostenol and HLT were assessed by comparing survival in this group with that of 120 patients at the Mayo Clinic before HLT and epoprostenol treatment became available. PATIENTS AND INTERVENTIONS--Forty four patients were studied; 25 received continuous epoprostenol over a four year period (mean (SD) cardiac index 1.8 (0.4) 1 min-1 m-2 and mean (SD) pulmonary artery pressure (PAP) 70 (16) mm Hg) and 19 did not (cardiac index 2.1 (0.6) 1 min-1 m-2 and PAP 64 (13) mm Hg). Ten patients underwent HLT: seven had received epoprostenol, and three had not. RESULTS--The therapeutic intervention with epoprostenol, or HLT, or both improved survival compared with the Mayo clinic patients (p = 0.05). Most of the benefit was conferred by epoprostenol, which prolonged survival twofold from a median time of eight to 17 months and doubled the changes of successful HLT. The improved survival with epoprostenol was not related to its immediate capacity to cause pulmonary vasodilation. Those patients who had limited acute pulmonary vasodilation when treated with epoprostenol showed the greatest improvement in survival. CONCLUSIONS--These preliminary results indicate that those pulmonary hypertensive patients with the poorest chance of survival can be helped by epoprostenol and by HLT.

Full text

PDF
366

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asherson R. A., Higenbottam T. W., Dinh Xuan A. T., Khamashta M. A., Hughes G. R. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol. 1990 Oct;17(10):1292–1298. [PubMed] [Google Scholar]
  2. Christman B. W., McPherson C. D., Newman J. H., King G. A., Bernard G. R., Groves B. M., Loyd J. E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):70–75. doi: 10.1056/NEJM199207093270202. [DOI] [PubMed] [Google Scholar]
  3. D'Alonzo G. E., Gianotti L., Dantzker D. R. Noninvasive assessment of hemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension. Am Rev Respir Dis. 1986 Mar;133(3):380–384. doi: 10.1164/arrd.1986.133.3.380. [DOI] [PubMed] [Google Scholar]
  4. Fuster V., Steele P. M., Edwards W. D., Gersh B. J., McGoon M. D., Frye R. L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984 Oct;70(4):580–587. doi: 10.1161/01.cir.70.4.580. [DOI] [PubMed] [Google Scholar]
  5. Higenbottam T., Wheeldon D., Wells F., Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984 May 12;1(8385):1046–1047. doi: 10.1016/s0140-6736(84)91452-1. [DOI] [PubMed] [Google Scholar]
  6. Jones D. K., Higenbottam T. W., Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Br Heart J. 1987 Mar;57(3):270–278. doi: 10.1136/hrt.57.3.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kahaleh M. B., Osborn I., Leroy E. C. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med. 1982 May;96(5):610–613. doi: 10.7326/0003-4819-96-5-610. [DOI] [PubMed] [Google Scholar]
  8. Levine S. M., Gibbons W. J., Bryan C. L., Walling A. D., Brown R. W., Bailey S. R., Cronin T., Calhoon J. P., Trinkle J. K., Jenkinson S. G. Single lung transplantation for primary pulmonary hypertension. Chest. 1990 Nov;98(5):1107–1115. doi: 10.1378/chest.98.5.1107. [DOI] [PubMed] [Google Scholar]
  9. McCarthy P. M., Starnes V. A., Theodore J., Stinson E. B., Oyer P. E., Shumway N. E. Improved survival after heart-lung transplantation. J Thorac Cardiovasc Surg. 1990 Jan;99(1):54–60. [PubMed] [Google Scholar]
  10. McGavin C. R., Artvinli M., Naoe H., McHardy G. J. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J. 1978 Jul 22;2(6132):241–243. doi: 10.1136/bmj.2.6132.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Moncada S. Biology and therapeutic potential of prostacyclin. Stroke. 1983 Mar-Apr;14(2):157–168. doi: 10.1161/01.str.14.2.157. [DOI] [PubMed] [Google Scholar]
  12. Packer M. Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension? Chest. 1989 Jun;95(6):1173–1175. doi: 10.1378/chest.95.6.1173. [DOI] [PubMed] [Google Scholar]
  13. Palevsky H. I., Schloo B. L., Pietra G. G., Weber K. T., Janicki J. S., Rubin E., Fishman A. P. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989 Nov;80(5):1207–1221. doi: 10.1161/01.cir.80.5.1207. [DOI] [PubMed] [Google Scholar]
  14. Pietra G. G., Edwards W. D., Kay J. M., Rich S., Kernis J., Schloo B., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989 Nov;80(5):1198–1206. doi: 10.1161/01.cir.80.5.1198. [DOI] [PubMed] [Google Scholar]
  15. Reeves J. T., Groves B. M., Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis. 1986 Aug;134(2):342–346. doi: 10.1164/arrd.1986.134.2.342. [DOI] [PubMed] [Google Scholar]
  16. Reitz B. A., Wallwork J. L., Hunt S. A., Pennock J. L., Billingham M. E., Oyer P. E., Stinson E. B., Shumway N. E. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982 Mar 11;306(10):557–564. doi: 10.1056/NEJM198203113061001. [DOI] [PubMed] [Google Scholar]
  17. Rich S., Brundage B. H., Levy P. S. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation. 1985 Jun;71(6):1191–1196. doi: 10.1161/01.cir.71.6.1191. [DOI] [PubMed] [Google Scholar]
  18. Rich S., Dantzker D. R., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Koerner S. K. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug;107(2):216–223. doi: 10.7326/0003-4819-107-2-216. [DOI] [PubMed] [Google Scholar]
  19. Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):76–81. doi: 10.1056/NEJM199207093270203. [DOI] [PubMed] [Google Scholar]
  20. Rich S., Pietra G. G., Kieras K., Hart K., Brundage B. H. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med. 1986 Oct;105(4):499–502. doi: 10.7326/0003-4819-105-4-499. [DOI] [PubMed] [Google Scholar]
  21. Robin E. D. The kingdom of the near-dead. The shortened unnatural life history of primary pulmonary hypertension. Chest. 1987 Aug;92(2):330–334. doi: 10.1378/chest.92.2.330. [DOI] [PubMed] [Google Scholar]
  22. Rozkovec A., Stradling J. R., Shepherd G., MacDermot J., Oakley C. M., Dollery C. T. Prediction of favourable responses to long term vasodilator treatment of pulmonary hypertension by short term administration of epoprostenol (prostacyclin) or nifedipine. Br Heart J. 1988 Jun;59(6):696–705. doi: 10.1136/hrt.59.6.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rubin L. J., Mendoza J., Hood M., McGoon M., Barst R., Williams W. B., Diehl J. H., Crow J., Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990 Apr 1;112(7):485–491. doi: 10.7326/0003-4819-112-7-485. [DOI] [PubMed] [Google Scholar]
  24. Szczeklik J., Szczeklik A., Nizankowski R. Haemodynamic changes induced by prostacyclin in man. Br Heart J. 1980 Sep;44(3):254–258. doi: 10.1136/hrt.44.3.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Walcott G., Burchell H. B., Brown A. L., Jr Primary pulmonary hypertension. Am J Med. 1970 Jul;49(1):70–79. doi: 10.1016/s0002-9343(70)80115-2. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES